# Maia Biotechnology

Source: https://onco.cc/companies/maia-biotechnology/  
OnCo record `maia-biotechnology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Maia Biotechnology is a United States-based biotechnology company running 2 late-stage cancer trials in non-small-cell lung cancer.

## Summary

Maia Biotechnology, based in Chicago, the United States, is a biotechnology company. Maia Biotechnology is a clinical-stage biopharmaceutical company that develops telomere-targeting immunotherapies for cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3) in non-small-cell lung cancer. The largest, NCT06908304 (A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC), plans to enrol 300 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor
- HQ: Chicago
- Type: biotech
- Website: https://www.maiabiotech.com

## Sources

- Official website: https://www.maiabiotech.com
- ClinicalTrials.gov: trials led by Maia Biotechnology: https://clinicaltrials.gov/search?lead=Maia%20Biotechnology

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- trials: [A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC](https://onco.cc/trials/nct06908304/), [THIO Sequenced With Cemiplimab in Advanced NSCLC](https://onco.cc/trials/nct05208944/)

---
JSON: https://onco.cc/api/v1/entities/maia-biotechnology.json